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Abstract
Dromedary camels have been shown to be the main reservoir for human Middle East respira-
tory syndrome (MERS) infections. This systematic review aims to compile and analyse all
published data on MERS-coronavirus (CoV) in the global camel population to provide an
overview of current knowledge on the distribution, spread and risk factors of infections in
dromedary camels. We included original research articles containing laboratory evidence of
MERS-CoV infections in dromedary camels in the field from 2013 to April 2018. In general,
camels only show minor clinical signs of disease after being infected with MERS-CoV.
Serological evidence of MERS-CoV in camels has been found in 20 countries, with molecular
evidence for virus circulation in 13 countries. The seroprevalence of MERS-CoV antibodies
increases with age in camels, while the prevalence of viral shedding as determined by
MERS-CoV RNA detection in nasal swabs decreases. In several studies, camels that were
sampled at animal markets or quarantine facilities were seropositive more often than camels
at farms as well as imported camels vs. locally bred camels. Some studies show a relatively
higher seroprevalence and viral detection during the cooler winter months. Knowledge of
the animal reservoir of MERS-CoV is essential to develop intervention and control measures
to prevent human infections.
Introduction
Middle East respiratory syndrome (MERS) is a highly fatal respiratory tract disease in humans
that was first detected in 2012 in the Kingdom of Saudi Arabia (KSA) [1]. After its first detec-
tion, MERS-coronavirus (MERS-CoV) was being reported in human patients across the
Arabian Peninsula, with occasional travel-related cases in other continents. As of the end of
March 2018, a total of 2189 human laboratory-confirmed cases from 27 countries have
been reported to the World Health Organisation (WHO), including 782 associated deaths [2].
Dromedary camels (Camelus dromedaries) have been shown to be the natural reservoir from
where spill-over to humans can occur [3, 4]. Human-to-human infection is also reported fre-
quently, especially in healthcare settings [5]. Sustained human-to-human transmission outside
of hospital settings has not been shown yet [6]. Direct or indirect human contact with camels
has resulted in repeated introductions of MERS-CoV into the human population [7]. It has
been suggested that camels may have acquired MERS-CoV from a spill-over event from a
bat reservoir, but evidence for that remains inconclusive [8]. Infections with MERS-CoV gen-
erally are thought to be mild or inapparent in camels [9], and are therefore of low economical
or animal welfare significance.
This systematic review was done to compile and analyse all published data on MERS-CoV
in the global camel population to provide an overview of current knowledge on the distribu-
tion, spread and risk factors of MERS-CoV infections in dromedary camels as a basis for the
design of intervention and control measures to prevent human infections.
Material and methods
On 2 May 2018, a literature search on PubMed was performed, using the terms ‘middle east
respiratory syndrome coronavirus’ and ‘MERS-CoV’. Using the term ‘MERS’ did not result in
any additional articles that fit the scope of this review. Only articles published in English were
included. Two reviewers individually selected all original research articles containing labora-
tory evidence of MERS-CoV infections in dromedary camels in the field. Articles that were
mentioned in Food and Agriculture Organization (FAO) updates [10] or in the references
of included publications, but did not appear in the PubMed search were added.
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Subsequently, abstracts, follow-up studies of MERS-CoV-positive
camels and genome studies without prevalence data were
excluded from the analysis. Data on variables such as year of sam-
pling, country, region, age, sex and animal origin were extracted
and analysed. For each variable, the number of positive camels,
total number of camels tested and the median percentage positiv-
ity was calculated. Data from experimental infection studies were
not included in this analysis, but they were included in the review
to provide additional information and context to the field studies.
Additional information on the distribution and trade of dromed-
ary camels was collected from references in the publications on
MERS-CoV in camels and extracted from official FAO and
World Organisation for Animal Health (OIE) databases
[11, 12]. The additional literature on camel trade was collected
in a less systematic way from PubMed.
Results
Literature search
The literature search resulted in a total of 53 papers (Fig. 1).
Forty-three research papers described the results of cross-
sectional studies in dromedary camel populations, six papers
described outbreak investigations, including an analysis of camel
samples, and four papers described longitudinal studies. In
total, 33 papers describe camel studies in the Middle East, 13
studies investigated camels from Africa and the remaining seven
surveys were from Spain, Australia, Japan, Bangladesh and
Pakistan (Table 1).
Distribution and trade of camels
Most recent FAO statistics estimate the world population of camel
to be around 29 million [11], of which approximately 95% are
dromedary camels [13]. However, it is believed that the true
population size is even larger due to inaccurate statistics and
feral camels, such as the feral dromedary camel population in
Australia that is estimated to be around 1 million [14]. Over
80% of the camel population lives in Africa. The main camel
countries are Chad (6 400 000), Ethiopia (1 200 000), Kenya (2
986 057), Mali (1 028 700), Mauritania (1 379 417), Niger (1 698
110), Sudan (4 830 000), Somalia (7 100 000) and Pakistan (1
000 000) [12] (Table 2).
A large number of camels are being transported from the Horn
of Africa to the Middle East each year. These are mainly meat
camels coming from the east of Africa going to Egypt, Libya
and the Gulf states, and Sudanese camels that are being imported
into the Middle East to participate in camel racing competi-
tions [15]. For example, the FAO reported that Somalia exported
77 000 camels in 2014 [16]. The largest camel market in Africa is
the Birqash market near Cairo (Egypt), where camels from Sudan
and Ethiopia are most common, but trade routes include animals
from Chad, Somalia, Eritrea and Kenya [17]. Imported camels are
usually quarantined for 2–3 days at the border before they are
allowed to enter Egypt [17]. Most Somali and Sudanese camels
that are exported to the KSA are shipped from the ports of
Berbera and Bosaso in North Somalia to the KSA ports of Jizan
and Jeddah [15].
Clinical and pathological features of MERS-CoV infections in
dromedary camels
In general, only minor clinical signs of disease have been observed
in animals infected with MERS-CoV and most MERS-CoV infec-
tions do not appear to cause any symptoms [9]. Disease symp-
toms that have been described after experimental and field
infections are coughing and sneezing, respiratory discharge,
fever and loss of appetite [18–20]. Although MERS-CoV RNA
can be detected in several organs after experimental infection,
in studies of natural infectious virus it has only been detected
in the tissues of the upper and lower respiratory tract and regional
lymph nodes of the respiratory system in part of the infected
camels. Histologically, a mild-to-moderate inflammation and
necrosis could also be seen on the upper and lower respiratory
tract. No viral antigen or lesions were detected in the alveoli.
Histopathological examination showed that the nasal respiratory
epithelium is the principal site of MERS-CoV replication in
camels [18, 21].
Virus shedding and antibody response
In one study investigating experimental infection of camels,
MERS-CoV shedding started 1–2 days post-infection (dpi). In
that study, infectious virus could be detected until 7 dpi, and
viral RNA until 35 dpi in nasal swab samples and, in lower
Fig. 1. Results literature search.
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Table 1. Summary table of included papers
References Study design Country of origin Year
MERS-CoV RNA
presence MERS-CoV seroprevalence Sex Age Imported/local Sampling location Other animals tested
Hemida et al.
[50]
Cross-
sectional
KSA 2010–2013 ppNT: 90% (280/310) <1Y: 72% (47/65)
1–3Y: 95% (101/106)
4–5Y: 97% (74/76)
>5Y: 92% (58/63)
Sheep 0% (0/100)
Goat 0% (0/45)
Chicken 0% (0/240)
Cattle 0% (0/50)
Perera et al.
[48]
Cross-
sectional
Egypt 2013 MN: 98% (108/110) Abattoir Goat 0% (0/13)
Sheep 0% (0/5)
Buffalo 0% (0/8)
Cattle 0% (0/25)
Swine 0% (0/260)
Wild birds (Hong Kong)
0% (0/204)
Reusken
et al. [4]
Cross-
sectional
Oman
Spain (Canary
islands)
2013
2012–2013
pMA: 100% (50/50)
14% (15/105)
Female: 100% (50/50)
Male: 4% (2/50)
Female:13% (7/55)
8–12Y: 100% (50/50) Local
Morocco: 0% (0/3)
Breeding farm
Tourist farm
Bactrian camel 0% (0/4)
Alpaca 0% (0/24)
Llama 0% (0/7)
Guanaco 0% (0/2)
Cattle 0% (0/40)
Goat 0% (0/120)
Sheep 0% (0/40)
Reusken
et al. [51]
Cross-
sectional
Jordan 2013 Faecal: 0% (0/11) pMA: 100% (11/11) Male: 100% (11/11) 3–14m: 100% (11/11) Sheep: 0% PCR (0/126)
pMA: 5% (6/126): 0%
(0/126)
Cattle: PCR 0% (0/91)
pMA: 0% (0/91)
Goat: pMA/0% (0/150)
Alagaili et al.
[31]
Cross-
sectional
KSA 1992
1993
1994
1996
2004
2009
2010
2013 Nasal: 25% (51/202)
ELISA: 100% (1/1)
100% (2/2)
93% (114/123)
100% (6/6)
100% (6/6)
78% (64/82)
84% (37/44)
74% (150/203)
<2Y: 52% (50/96)
2–5Y: 88% (29/33)
>5Y: 98% (54/55)
Goat: PCR 0% (0/36)
ELISA 0% (0/35)
Sheep: PCR 0% (0/78)
ELISA 0% (0/112)
Alexandersen
et al. [49]
Cross-
sectional
UAE
USA and Canada
2005
2000–2001
VNT/ELISA: 82% (9/11)
0% (0/6)
Male: 50% (2/4)
Female: 100% (7/7)
Sheep 0% (0/20)
Horse 0% (0/3)
Azhar et al.
[66]
Memish et al.
[67]
Human
outbreak
investigation
KSA 2013 Nasal: 11% (1/9)
Milk, urine, rectal: 0%
(0/11)
IFA/ELISA: 100% (9/9) <1Y: PCR 33% (1/3)
IFA/ELISA: 100% (3/3)
2–5Y: IFA/ELISA 100% (1/1)
>5Y: IFA/ELISA 100% (5/5)
Farm
Chu et al. [9] (Multiple)
cross-
sectional
Egypt 2014 Nasal: 4% (4/93)
Nasal: 0% (0/17)
ppNT: 92% (48/52) >6Y: 92% (48/52) Sudan or Ethiopia
Local
Abattoir
Farm
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Table 1. (Continued.)
References Study design
Country of origin
Year
MERS-CoV RNA
presence
MERS-CoV seroprevalence
Sex Age Imported/local Sampling location Other animals tested
Corman et al.
[36]
Cross-
sectional
Kenya Total
1992
1996
1998
1999
2000
2007
2008
2013
ELISA, total: 30%
(228/774)
5% (1/22)
5% (2/37)
3% (2/62)
27% (71/266)
32% (82/258)
0% (0/28)
56% (103/183)
17% (8/47)
Adult: 37% (226/70)
Juvenile: 25% (15/59)
Pakistan
Local
Local
Local
Local
Local
Local
Local
Total, farm: 9% (40/436)
Total, nomadic: 52%
(229/439)
Farm
Farm
Farm: 0% (0/50)
Nomadic: 17% (2/12)
Farm: 18% (32/175)
Nomadic: 43% (39/91)
Farm: 4% (4/112)
Nomadic: 53%
(78/146)
Isolated
Nomadic
Farm: 3% (1/40)
Nomadic: 100% (7/7)
Haagmans
et al. [3]
Human
outbreak
investigation
Qatar 2013 Nasal: 86% (12/14)
Oral: 0% (0/14)
Rectal: 0% (0/19)
IFA/VNT: 100% (14/14) Farm
Hemida et al.
[19]
Longitudinal KSA 2013–2014 Nasal: 33% (9/27)
Oral: 0% (0/17)
Rectal: 3% (1/37)
<2Y: 39% (7/18)
6–14Y: 22% (2/9)
Farm
Hemida et al.
[68]
Cross-
sectional
KSA
Australia
Egypt
1993
2014
2014
ppNT: 90% (118/131)
ppNT: 0% (0/25)
ppNT: 100% (7/7)
Farm
Farm and abattoir
(feral)
Abattoir
Meyer et al.
[37]
Cross-
sectional
UAE 2003
2013
IFA: 100% (151/151)
IFA: 96% (481/500)
>2Y: 100% (151/151)
2–8Y: 89% (89/100)
>2Y: 89% (89/100) KSA, Sudan, Pakistan
and Oman
UAE
Farm (racing): 89%
(89/100)
Farm (livestock camels):
100% (217/218)
Isolated: 0% (0/5)
Bactrian camel 0% (0/16)
Muller et al.
[32]
Cross-
sectional
Somalia
Sudan
Egypt
1983–1984
1983
1997
ELISA: 84% (72/86)
mNT: 81% (70/86)
ELISA: 84% (159/189)
mNT: 81% (153/189)
ELISA: 81% (35/43)
mNT: 79% (34/43)
Female: ELISA 84%
(159/189)
>6Y: 84% (159/189)
Abattoir
Farm
Nowotny
et al. [69]
Cross-
sectional
Oman 2013 Nasal: 7% (5/76)
Raj et al. [70] Cross-
sectional
Qatar 2014 Nasal: 2% (1/53)
Reusken
et al. [28]
Cross-
sectional
Qatar 2013 Nasal: 15% (5/33)
Rectal: 9% (3/33)
Milk: 15% (5/33)
pMA: 100% (33/33)
Milk: pMA 100% (12/12),
75% (9/12)
Female: 15% (5/33) >5Y: PCR 42% (5/12) ELISA
100% (12/12)
Farm
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Reusken
et al. [28]
Cross-
sectional
Nigeria
Tunisia
Ethiopia
2010–2011
2009
2010–2011
pMA: 28% (100/358)
pMA: 49% (99/204)
pMA: 96% (181/188)
4–15Y: 28% (100/358)
⩽2Y: 30% (14/46)
>2Y: 54% (85/158)
⩽2Y: 94% (29/31)
>2Y: 97% (152/157)
Abattoir also serves
Chad, Niger, CAR
Abattoir
Farm
Woo et al.
[25]
Cross-
sectional
UAE 2013 Faecal: 5% (14/293) WB: 98% (58/59)
IFA: 100% (59/59)
<1Y: PCR 21% (13/61): 98%
(54/55)
⩾1Y: PCR: 0% (1/232):
100% (4/4)
Farm
Al Hammadi
et al. [71]
Human
outbreak
investigation
UAE 2015 Nasal: 100% (8/8) ppNT: 100% (5/5) Female: 100% (5/5) <1Y: 100% (4/4)
10Y: 100% (1/1)
Oman Border screening
Chu et al.
[72]
Cross-
sectional
Nigeria 2015 Nasal: 11% (14/132) ppNT: 95% (125/131) >6Y: 95% (125/131) Abattoir
Crameri et al.
[58]
Cross-
sectional
Australia 2013–2014 VNT: 0% (0/307) Abattoir: 231
Feral camel muster: 76
Deem et al.
[40]
Cross-
sectional
Kenya 2013 pMA: 50% (166/335) <6m: 36% (22/61)
6m–2Y: 30% (24/80)
>2Y: 62% (120/194)
Farm: 48% (124/261)
Nomadic: 57% (42/74)
Farag et al.
[26]
Cross-
sectional
Qatar 2014 Nasal: 60% (61/101)
Oral: 23% (23/102)
Rectal: 15% (15/103)
Bronchial: 7% (7/101)
Lymph nodes: 9%
(5/53)
pMA: 97% (100/103) <1Y: PCR: 68% (50/73)
⩾1Y: PCR: 39% (11/28)
Abattoir
Gutierrez
et al. [33]
Cross-
sectional
Canary Islands 2015 ELISA: 4% (7/170) Male: 0% (0/101)
Female: 10% (7/69)
⩾2Y: 4% (7/170)
All positives were aged
20–26Y
African: 41% (7/17)
Local: 0% (0/153)
Farm
Khalafalla
et al. [20]
Longitudinal KSA 2013–2014 Nasal: 29% (28/96)
Lung tissue 62%
(56/91)
<4Y: 42% (15/36)
⩾4Y: 22% (13/60)
Abattoir, live animal
market, veterinary
hospital
Shirato et al.
[47]
Cross-
sectional
Japan 2015 Nasal: 0% (0/4)
Rectal: 0% (0/18)
Oral: 0% (0/10)
ELISA: 0% (0/5) Male: nasal PCR 0% (0/1)
0% (0/1)
Female: nasal PCR 0%
(0/3) 0% (0/4)
<2Y: 0% (0/1)
>5Y: PCR 0% (0/3) 0% (0/3)
Zoo Bactrian camels:
PCR: 0% (0/6)
ELISA: 0% (0/6)
Wernery
et al. [55]
Cross-
sectional
UAE 2015 Nasal: 0% (0/254)
Milk: 0% (0/1333)
ELISA: 92% (234/254) Female: ELISA 99%
(132/133)
0–3m: ELISA: 75% (24/32)
4m: ELISA: 79% (11/14)
5–6m: ELISA: 89% (41/46)
7–12m: ELISA: 90% (26/29)
>12m: ELISA: 99%
(132/133)
Farm
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Table 1. (Continued.)
References Study design
Country of origin
Year
MERS-CoV RNA
presence
MERS-CoV seroprevalence
Sex Age Imported/local Sampling location Other animals tested
Wernery
et al. [55]
Cross-
sectional
UAE 2015 Nasal: 5% (45/871) ELISA: 93% (786/843) <1Y: PCR: 35% (24/68)
ELISA 85% (92/108)
2–4Y: PCR: 3% (10/344)
ELISA 97% (328/340)
>4Y: PCR: 0% (0/250) ELISA
96% (298/310)
Farm
Yusof et al.
[73]
Cross-
sectional
UAE 2014 Nasal: 2% (126/7803) KSA
Oman
Border screening: 2%
(70/4617)
Border screening: 1%
(31/2853)
Abattoir: 8% (25/303)
Public escort and zoo:
0% (0/30)
Meyer et al.
[30]
Longitudinal
11 calf-dam
pairs
UAE 2014–2015 At 6m (nasal): 18%
(2/11) of calves, no
dams
At day 0: MN/ELISA 0%
(0/11)
Maternal Ab peak at day 7
At 5–6m: 45% (5/11)
At 12m: 100% (22/22)
Dams: ELISA: 100% (11/11) Farm
Miguel et al.
[46]
Cross-
sectional
Kazakhstan 2015 ppNT: 0% (0/455) Female: 0% (0/455) Farm Bactrian camels:
ppNT: 0% (0/95)
Muhairi et al.
[29]
Human
outbreak
investigation
UAE 2014 Farms MERS patients
(n = 2):
Nasal: 10% (15/155)
Surrounding farms:
Nasal: 3% (27/992)
Farm Sheep: 0% (0/34)
Sabir et al.
[22]
Cross-
sectional
KSA 2014–2015 Nasal: 12%
(159/1309)
Rectal: 0% (0/304)
⩽6m:15% (28/190)
6m–1Y: 18% (58/315)
1–2Y: 8% (42/509)
2–4Y: 10% (20/206)
>4Y: 11% (5/46)
Local: 15% (133/893)
Sudan: 6% (7/116)
Somalia: 7% (19/291)
Abattoir: 0% (0/14)
Farm: 11% (14/133)
Market: 12% (145/1162)
Al Salihi et al.
[74]
Cross-
sectional
Iraq 2015–2016 15% (15/100)
(94 nasal, 6
oropharyngeal
swabs)
Male: 18% (3/17)
Female: 14% (12/83)
<1Y: 0% (0/9)
1–5Y: 15% (6/41)
5–10Y: 16% (6/38)
>10Y: 25% (3/12)
Farm: 16% (13/80)
Abattoir: 10% (2/20)
Ali et al. [17] Cross-
sectional
Egypt 2014–2016 Nasal: 15%
(435/2825)
Rectal: 15% (18/114)
Milk: 6% (12/187)
Urine: 0% (0/26)
MN: 71% (1808/2541)
Milk: 20% (38/187)
Male: PCR 21%
(300/1439) MN: 72%
(905/1254)
Female: PCR 11%
(115/1089) MN 66%
(724/1090)
<2Y: PCR 16% (97/591) MN
37% (221/596)
>2Y: PCR 10% (228/2234)
MN 82% (1587/1945)
Local: PCR 12%
(192/1658) MN 61%
(1015/1655)
Sudan, Somalia and
Ethiopia: PCR 21%
(243/1167) MN 90%
(793/886)
Market: PCR 2.5%
(4/159) MN 92%
(159/172)
Nomadic: PCR 1%
(3/282) MN 72%
(202/282)
Farm: PCR 14%
(189/1376) MN 59%
(813/1373)
Quarantine: PCR 36%
(153/424) MN 95%
(342/361)
Abattoir: PCR 15%
(86/584) MN 83%
(292/353)
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Ali et al. [27] Cross-
sectional
Egypt 2014–2015 Nasal: 4% (41/1078) MN: 84% (871/1031) Male: PCR 3% (21/798)
MN 85% (651/765)
Female: PCR 7% (20/280)
MN 83% (220/266)
⩽2Y: PCR 2% (2/82) MN
52% (42/81)
>2Y: PCR 4% (39/996) MN
87% (829/950)
Local: PCR 1%
(2/340) MN 76%
(257/339)
East Africa: PCR 3%
(4/115) MN 72%
(71/98)
Sudan: PCR 6%
(35/623) MN 91%
(543/594)
Market: PCR 3% (9/290)
MN 94% (273/289)
Village: PCR 1% (2/340)
MN 76% (256/339)
Quarantine: PCR 2%
(4/164) MN 96%
(1557/164)
Abattoir: PCR 9%
(26/284) MN 77%
(184/239)
Cattle: PCR 0% (0/35) MN
0% (0/35)
Sheep: PCR 0% (0/51)
MN 2% (1/51)
Goat: PCR 0% (0/36) MN
0% (0/36)
Buffalo: PCR 0% (0/4)
MN 0% (0/4)
Donkey: PCR 0% (0/15)
MN 0% (0/15)
Horse: PCR 0% (0/4) MN
0% (0/4)
Bat: 0% (0/91)
Doremalen
et al. [23]
Cross-
sectional
Jordan 2016 Nasal: 67% (28/42)
Rectal: 0% (0/42)
Urogenital: 0% (0/42)
ELISA 82% (37/45) <1Y: PCR 61% (11/18)
ELISA 78% (14/18)
1–2Y: PCR 92% (12/13)
ELISA 69% (9/13)
2–5Y: PCR 50% (5/10)
ELISA 100% (10/10)
>5Y: PCR 0% (0/1) ELISA
100% (4/4)
Farm PCR 77% (17/22)
ELISA 77% (17/22)
Nomadic: PCR (10/20)
ELISA 87% (20/23)
Cattle: ELISA 0% (0/5)
Sheep: ELISA 0% (0/10)
Falzarano
et al. [53]
Cross-
sectional
Mali 2009–2010 ELISA: 88% (502/571) Male: 86% (210/245)
Female: 92%
(302/328)
1–2Y: 83%
3–8Y: 91%
9–16Y: 88%
Farm Cattle and sheep: 0%
(0/10)
Hemida et al.
[24]
Longitudinal KSA 2014–2015 Nasal: 4% (3/70)
Rectal: 0% (0/70)
ppNT: 100% (70/70) ⩽2Y: 19% (3/16)
>2Y: 0% (0/39)
Farm
Kasem et al.
[38]
Human
outbreak
investigation
KSA 2014–2016 Nasal: 10% (75/780)
(camels with MERS
patients contact)
ELISA: 71% (422/595) Male: PCR 20% (49/245)
ELISA 84% (127/152)
Female: PCR 5% (26/535)
ELISA 67%
(295/443)
⩽2Y: PCR 15% (46/298)
ELISA 57% (145/251)
2–4Y: PCR 6% (13/202)
ELISA 79% (120/156)
4–6Y: PCR 4% (6/144)
ELISA 81% (79/98)
>6Y: PCR 7% (10/136)
ELISA 87% (78/90)
Farm
Miguel et al.
[39]
Cross-
sectional
Burkina Faso
Ethiopia
Morocco
2015 Nasal: 5% (27/525)
Nasal: 11% (70/632)
Nasal: 1% (5/343)
ppNT: 80% (421/525)
95% (600/632)
77% (265/343)
Seropositivity and CR-
positive rate higher in
females
Seropositivity rates
increased, MERS RNA
detection rate decreased
with age
Munyua et al.
[75]
Cross-
sectional
Kenya 2013 ELISA 90% (789/877) Male: 81% (173/213)
Female 93% (616/664)
1–4Y: 73% (209/285)
4–6Y: 99% (116/117)
>6Y: 98% (466/476)
Farm: 71% (10/14)
Nomadic: 91%
(698/771)
Saqib et al.
[35]
Cross-
sectional
Pakistan 2012–2015 ELISA: 56% (315/565)
MN: 39% (223/565)
Male: ELISA/MN: 44%
(96/217)
Female: ELISA/MN: 36%
(127/348)
⩽2Y: MN 29% (26/89)
2–5Y: 30% (62/208)
5–10Y: 51% (92/180)
>10Y: 49% (43/88)
Yusof et al.
[41]
Li et al. [76]
Cross-
sectional
UAE 2015 Nasal: 29% (109/376) Male: 27% (73/269)
Female: 31% (33/107)
<1Y: 32% (81/255)
>1Y: 21% (25/121)
Local: 25% (53/210)
Oman: 50% (53/106):
5% (3/60)
Market
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amounts, in oral swab samples [18]. No infectious virus or viral
RNA was detected in faecal or urine samples [18]. Viral RNA
detection in nasal, but also rectal swabs of camels after experi-
mental infection until day 14, has been confirmed in a recent vac-
cine study [21].
In the field surveys included in this review, MERS-CoV RNA
has been described in rectal swab samples, although other field
studies report negative results [3, 22–24] and when viral RNA
can be detected, the positivity rate of rectal swabs is lower com-
pared with nasal swab samples [19, 25–27]. Oral swabs are usu-
ally negative or show a lower positivity rate even when nasal
swabs test positive for MERS-CoV RNA [3, 19, 26]. Some stud-
ies have reported MERS-CoV RNA in milk samples [27, 28].
Longitudinal studies of camel herds show that PCR results of
nasal swabs can remain positive after 2 weeks [27, 29]. When
an interval of sampling of 1 or 2 months was maintained,
nasal swabs become negative for viral RNA in the next sampling
round [24, 30].
MERS-CoV infections have also been detected in camels with
MERS-CoV antibodies, both in calves with maternal antibodies as
well as older camels that had already acquired antibodies from a
previous infection. However, virus replication and thus the virus
load is generally lower in infected seropositive animals compared
with seronegative camels [19, 21, 23, 24, 30, 31].
Little is known about the longevity of antibody titres after
infection from longitudinal studies. A study following camels on
a closed farm found that neutralizing antibodies remained con-
sistent during a year [30], while other studies found that antibody
titres rapidly drop by 1–4-fold within a period often as short as 2
weeks [24, 27].
Worldwide distribution of MERS-CoV in dromedary camels
The first evidence of MERS-CoV in camels described so far is the
detection of antibodies to MERS-CoV in camel sera from Somalia
and Sudan from 1983 of which 81% tested positive [32].
Additional serological evidence of the widespread presence of
MERS-CoV infection in camels, included in this review, has
been found in 18 additional countries: Bangladesh, Burkina
Faso, Egypt, Ethiopia, Iraq, Israel, Jordan, Kenya, KSA, Mali,
Morocco, Nigeria, Oman, Pakistan, Qatar, Spain, Tunisia and
the UAE (Fig. 2). In addition, Promed mail reported that
virus-positive camels had been found in Kuwait and Iran, the
latter reportedly in imported animals (Archive number
20140612.2534919 and 20141029.2912385). In 11 countries, sero-
logical findings were complemented with the finding of viral RNA
in dromedary camels: Burkina Faso, Egypt, Ethiopia, Iraq, Jordan,
KSA, Morocco, Nigeria, Oman, Qatar and the UAE.
Investigations of MERS-CoV circulation amongst dromedary
camels in Australia, Japan, Kazakhstan, USA and Canada did
not find any proof of MERS-CoV circulation. All countries
where MERS-CoV circulates in the camel population, with the
exception of Spain (Canary Islands), Pakistan and Bangladesh,
are located in the Middle East or Africa [4, 33]. One out of 17
camels that had MERS-CoV antibodies in Bangladesh was born
in Bangladesh, 16 others were imported from India [34].
However, there have not been any additional reports of MERS-
CoV in camels in India. There is no record of foreign origin of
the seropositive camels from Pakistan [35]. Moreover, in previous
studies there had already been evidence of seropositive camels that
originate from Pakistan [37, 58].Ta
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When combining serology data from all papers included in
this review, the overall median seroprevalence of camels in
Africa is 81% (6106/8526; range 28–98%), compared with a
median seroprevalence of 93% (3230/3846; range 53–100%) in
camels from the Middle East. Based on viral shedding studies
from African countries, the median rate of viral shedding was
5% (1108/6318; range 1–15%), compared with 12% in camels
from the Middle East (1191/14902; range 0–100%).
Risk factors of MERS-CoV in dromedary camels
Age
The seroprevalence of MERS-CoV antibodies increases with age
in camels, while the fraction of camels that test positive for
MERS-CoV RNA in their nasal swabs decreases with age [17,
31, 36, 38, 39]. When all serological results of papers that included
sufficient age information is combined, the median seropreva-
lence of camels aged under 2 years is 52% (992/1972; range
0–100%), while the age groups 2–5 years (702/924; range 30–
100%) and over 5 years old (1226/1370; range 0–100%) had a
combined median seroprevalence of 97%. In the virological stud-
ies reporting age breakdown, the median rate of nasal shedding in
0–2 years old camels was 34% (718/2612; range 0–100%) of cases,
compared with 2% (91/1142; range 0–100%) in camels older than
2 years.
Sex
Some individual studies show a significantly higher seropreva-
lence in female camels compared with males [27, 39], while others
show the opposite [38] or do not find any significant difference
[17, 35]. Similar disagreeing results are published for the presence
of MERS-CoV RNA in male vs. female camels [17, 27, 38, 39].
In the studies in this review where sex of camels was recorded,
a total of 4810 serum samples from female camels and 3458 sam-
ples from male camels were collected and analysed for MERS-
CoV antibodies, compared with 2007 vs. 2505 nasal swabs for
viral RNA testing. Approximately three times more female camels
were sampled at farms, while male camels were in the majority in
studies that looked at MERS-CoV prevalence of camels at slaugh-
terhouses, live animal markets and quarantine areas. The overall
median seroprevalence of male and female camels in our review
is 50% and 67%, respectively (range 0–100%; excluding results
from Israel and Kazakhstan). The median percentage of presence
of viral RNA is 18% in nasal swabs of male camels (range 0–21%)
compared with 9% in female camels (range 0–100%), in our
review.
Sampling location and herd characteristics
In several studies, camels that were sampled at animal markets or
quarantine facilities were seropositive more often than camels at
farms [17, 22, 27, 34]. Combining serological laboratory results
of camels in our review with sufficient background information
with regard to the sampling location does not result in the
same pattern, with a median seroprevalence of 84% (5632/8115;
range 0–100%; excluding Australia and Spain) in camels from
farms and 80% (943/1005; range 28–98%) in the camel popula-
tion sampled at markets and quarantine facilities. Studies in
Egypt found a significantly higher PCR positivity rate in camels
sampled in abattoirs or quarantine facilities, but these results
could not be confirmed by other papers in this review [17, 27].
When comparing differences in seroprevalence or virus RNA-
positive rate in nomadic vs. sedentary camel herds, some authors
did not find a statistical difference between the two herd manage-
ment types [39, 40], while others found some evidence of higher
seroprevalences in nomadic herds [27, 36]. One study in Kenya
looked at the differences between herds with different levels of
Table 2. Camel population and density
Country
Camel population
(OIE, 2016)
Camel density
(OIE, 2016)
(Animals per
square kilometre)
Africa
Algeria 354 565 (OIE, 2014) 0.15 (OIE, 2014)
Burkino Faso 19 097 0.07
Djibouti 50 000 2.17
Egypt 66 233 0.07
Eritrea 385 283 3.18
Ethiopia 1 200 000 1.06
Kenya 2 986 057 5.12
Libya 110 000 0.06
Mali 1 028 700 0.83
Mauritania 1 379 417 (OIE, 2013) 1.34 (OIE, 2013)
Morocco 197 550 (OIE, 2014) 0.44 (OIE, 2014)
Niger 1 698 110 (OIE, 2013) 1.34 (OIE, 2013)
Nigeria 279 397 0.3
Sudan 4 830 000 1.93
Somalia 7 100 000 11.13
Chad 6 400 000 4.98
Tunisia 56 021 0.34
Middle East/Central Asiaa
Afghanistan 175 270 0.21
Indiab 400 000 (OIE, 2015) 0.12 (OIE, 2015)
Iranb 171 500 0.10
Iraq 81 205 0.19
Jordan 10 872 (OIE, 2014) 0.12 (OIE, 2014)
Kazakhstanb 170 513 0.06
Kuwait 80 790 4.53
Oman 257 713 1.21
Pakistanb 1 000 000 1.24
Qatar 77 417 (OIE, 2014) 6.77 (OIE, 2014)
Saudi Arabia 481 138 0.25
Syria 45 610 0.25
Turkmenistanb 122 900 0.25
UAE 392 667 4.74
Uzbekistanb 14 800 0.03
Yemen 459 366 0.87
aExcluding China and Mongolia because the large majority of camel population are Bactrian
camels.
bCamel population exists of both dromedary and Bactrian camels[66].
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isolation, and did not find significant differences in MERS-CoV
antibody levels [40].
Animal origin
Most studies that compared local camels with imported camels
suggested that imported camels are seropositive for MERS-CoV
more often [9, 17, 27, 34, 41], although not all differences were
significant.
Two studies in Egypt found a significantly higher RNA posi-
tivity rate in imported camels from East Africa compared with
domestically bred camels [17, 27], while another study executed
in the KSA found a significantly higher number of MERS-CoV
RNA-positive results amongst local camels vs. camels from
Sudan and Somalia [22].
Seasonal variation in MERS-CoV circulation in the camel
population
Although MERS-CoV was detected almost year-round in camels,
some studies show a relatively higher seroprevalence and viral
detection during the cooler winter months [17, 20, 27, 38].
MERS-CoV in non-dromedary animals
MERS-CoV antibodies have been detected in llamas and alpacas
in Israel and in alpacas in Qatar [42, 43]. To date, no MERS-
CoV antibodies or viral RNA have been detected in Bactrian
camels [4, 37, 44–47] (Table 1 and Table 3). Swine, goats and
horses that were included in the field surveys in our review all
tested negative for MERS-CoV RNA and antibodies [4, 17, 31,
48–52]. MERS-CoV antibodies were detected in two studies in
sheep in Egypt and Qatar, although in very low numbers [17,
51]. However, most surveys that investigated sheep did not find
evidence of MERS-CoV infection or exposure [4, 23, 29, 31, 34,
48–51, 53].
Discussion
The publications in this review show that the MERS-CoV mainly
circulates in dromedary camel populations in the Middle East and
part of Africa, and has been infecting dromedary camels in Africa
for more than three decades. Antibodies have also been found in
Arabic camel sera from the early 90s [31, 32]. However, MERS-
CoV was discovered until 2012, after the first human cases
appeared [1], which is probably due to the minor clinical symp-
toms of MERS-CoV infections in camels [18]. Most camel surveys
were conducted in the Middle East and some northern and east-
ern African countries, but significant data gaps currently still exist
in the north and west of Africa, in countries that have camel
populations of 100 000 to more than a million animals, such as
Algeria, Libya, Mauritania and Niger. Even less is known about
the central Asian region. Some evidence of MERS-CoV circula-
tion in camels of Pakistan and Bangladesh was recently published,
but data is lacking from Afghanistan and India. Knowledge on the
presence of MERS-CoV in the animal reservoir is a crucial first
step to assess whether MERS-CoV could be a relevant public
health threat in these regions.
MERS-CoV infections are mainly detected in calves and young
camels [30, 31]. The research included in this review shows that
the IgG positivity rate increases gradually in dromedary camels
of increasing age while the MERS-CoV RNA detection rate decreases.
Maternal IgG antibodies in camels are acquired through the intake
of colostrum during the first 24 h post-parturition. After 24 h, anti-
body levels in the dam’s milk decrease rapidly [54]. One study
showed that maternal antibodies in calves peak at 7 days post-
parturition and decline in the following 6 months. After 5–6
months, over half of the calves did not have maternal neutralizing
antibodies in their serum any longer [30]. However, in other field
studies, the titre of MERS-CoV-specific antibodies is still low at 1
month of age and increases with age in dromedary calves [27,
55]. A lower or undetectable antibody levels in young camels is
likely to explain the higher MERS-CoV RNA detection rate. In
Fig. 2. Virological and serological evidence for MERS CoV in dromedary camels.
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adult camels, a much higher MERS-CoV seroprevalence can be
found, which is probably due to a long-lasting immune response
against a MERS-CoV infection or multiple re-infections with
MERS-CoV. Immunity is not sterilizing, as MERS-CoV infection
and shedding have also been shown in adult camels that have
MERS-CoV antibodies [19, 21, 23, 24, 30, 31].
Several articles have analysed seroprevalence and virus shed-
ding data in relation to factors, other than age, that may explain
differences in seroprevalence and MERS-CoV RNA-positive rate
in camels, such as sex, sampling location, herd characteristics
and animal origin. Our review shows that there is considerable
heterogeneity in results. In addition, comparison between studies
is difficult given the lack of standardisation of study designs. A
key factor to consider when comparing studies is the difference
in distribution of male and female camels amongst different dis-
ciplines of camel husbandry. Females are mainly used for milking
and reproduction. As a result, they often stay at farms. Male
camels, especially of young age (<1 year old), are the predominant
sex in slaughterhouses and amongst camels used for transport
[39, 56]. This also influences the risk profile of acquiring a
MERS-CoV infection. Female camels are in closer contact with
calves, who are more susceptible to infection and shed virus in
higher quantities compared with older camels [30]. On the
other hand, meat and transport camels (predominantly male) tra-
vel more, leading to increased contact with other camels and
camel herds, and therefore a higher chance of exposure to
MERS-CoV. Some papers in this review suggest that there is a
generally lower infection rate of domestically bred camels and
camels on farms compared with imported camels and camels
on animal markets or in quarantine facilities. This may be
explained by the same increased contact rate and mixing of
camel herds, leading to an increased chance of MERS-CoV expos-
ure and spread.
The increase in MERS-CoV circulation in winter and spring can
have multiple explanations. Firstly, the winter is the calving season
[10], which leads to a larger proportion of young animals that
usually have a higher number of MERS-CoV infections and virus
excretion. Moreover, in winter season, there is a major increase
of camel and human movements due to camel racing competitions,
camel breeding, trading and movements to grazing grounds, which
increases the chance of virus spread. Additionally, cooler tempera-
tures may facilitate coronavirus survival in the environment [57].
In experimental studies, llama’s and alpaca’s are shown to be
susceptible to infection with MERS-CoV [58, 59], which was con-
firmed by two papers in our review, describing serologically posi-
tive llamas and alpacas in Israel and alpacas with MERS-CoV
neutralizing antibodies in Qatar [42, 43]. In experimental settings,
animal-to-animal transmission has been shown for alpacas, mak-
ing them a possible risk population for human infections [58].
Two studies in our review also found anti-MERS-CoV antibodies
in sheep [17, 51] but experimental inoculation of sheep did not
result in MERS-CoV replication or antibody development
[59, 60]. However, the DPP4 receptor, the entry receptor for
MERS-CoV, is present in sheep tissues, making it possible for
the virus to bind to the sheep respiratory tract which may explain
the finding of MERS-CoV antibodies [61]. Pigs also express the
DPP4 receptor in their respiratory tract, and viral replication
in experimental settings has been shown for pigs, but no anti-
bodies or MERS-CoV RNA have been found in pigs during
field surveys [48, 59]. This may be explained by the limited
viral shedding in pigs and the absence of animal-to-animal trans-
mission [62, 63].
We show that dromedary camels are present in large parts of
the African and Asian continent, and that MERS infections in
dromedary camels are widespread. However, human infections
due to spill-over from the dromedary camel reservoir have not
been reported in Africa [10]. Several explanations for the differ-
ence in human cases between the Arabian Peninsula and Africa
have been suggested, such as differences in cultural habits,
camel husbandry, prevalence of comorbidities, under detection
or genetic factors in the local population [64]. Moreover, West
African viruses were found to be phylogenetically and
Table 3. MERS-CoV in non-dromedary animals in the field
Species Seroprevalence Viral RNAa
Bactrian camel 0% (0/505) (Netherlands, Chile [4]; UAE [37]; Mongolia [44]; China [45];
Kazachstan [46]; Japan [47])
0/390 (China [45], Mongolia [44])
Alpaca 24% (30/126) (Israel(+) [43], Netherlands, Chile [4])
100% (15/15), Qatar [42]b
0% (0/102) (Israel [43])
0% (0/15)(Qatar: [42])b
Llama 23% (6/26) (Israel (+) [43], Netherlands, Chile [4]) 0% (0/19) (Israel [43])
Guanaco 0% (0/2) (Chile [4]) –
Cattle and
buffalos
0% (0/258) (KSA [50]; Egypt [27, 48]; The Netherlands [4]; Jordan [23, 51]) 0% (0/35) (Egypt [27])
Swine 0% (0/260) (Egypt [48]) –
Sheep 0.2% (1/482)c (KSA [31, 50]; Egypt (+) [27, 48], The Netherlands [4]; Jordan [23, 51];
UAE [29, 49]; Bangladesh [34])
0% (0/307) (Jordan [51]; KSA [31]; Egypt [27];
Bangladesh [34])
Goats 0% (0/399) (KSA [31, 50]; Egypt [27, 48]; Spain, The Netherlands [4]; Jordan [51]) 0% (0/72) (KSA [31]; Egypt [27])
Horses,
donkeys
0% (0/22) (Egypt [27]; UAE [49])
0% (0/192)(UAE [52])b
0% (0/19) (Egypt [27])
Birds 0% (0/444) (KSA [50]; HK [48]) –
Bats 0% (0/91) (Egypt [27])
aMERS-CoV RNA in nasal swabs.
bArticles that were not included in the original literature search, because no camels were investigated in these studies.
cSix additional sera from sheep in Qatar tested positive by protein microarray (pMA), but could not be confirmed by NT.
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phenotypically distinct from the MERS-CoV viruses that caused
human disease in the Middle East [65].
Increased knowledge on the animal reservoir of MERS-CoV
needs to be combined with research on MERS prevalence and
risk factors in humans to assess the true public health risk.
Moreover, the absence of human disease, combined with the
mild symptoms in camels, caused by MERS, will likely have a
negative effect on the willingness to implement interventions
and the cost-effectiveness of possible interventions in some areas.
Conclusion
Since the discovery of MERS-CoV in 2012, the dromedary camel
has been identified as the animal reservoir of human infections
with the MERS-CoV. However, the exact route of human primary
infections is still unknown. Moreover, the scale of the spread and
prevalence of MERS-CoV in the camel reservoir is not fully
known yet since there is still a lack of MERS-CoV prevalence
data in some countries that harbour a very significant proportion
of the world camel population. However, knowledge of the animal
reservoir of MERS-CoV is essential to develop intervention and
control measures to prevent human infections. Prospective studies
that include representative sampling of camels of different age
groups and sex, within the different husbandry practices, are
needed to fully understand the patterns of MERS-CoV circula-
tion. Such studies are important as they may give more informa-
tion on critical control points for interventions to reduce the
circulation of MERS-CoV and/or exposure of humans.
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